NGS Cancer Gene Panel – Custom 4-Gene Marker Testing for Precision Oncology

Description

NGS Cancer Gene Panel – Custom 4-Gene Marker Testing for Precision Oncology

The NGS Cancer Gene Panel – Any Four Markers from Lab Tests Dubai is a customizable, next-generation sequencing (NGS) diagnostic test that allows oncologists to select four key cancer-related genes for focused, high-resolution tumor profiling perfect for personalized treatment planning, therapy selection, and hereditary risk assessment.

Unlike broad panels, this targeted 4-gene approach delivers:

• ✅ Faster turnaround
• ✅ Lower cost
• ✅ High clinical relevance
• ✅ Actionable results tailored to your cancer type

Choose from clinically significant genes such as:

• BRCA1 / BRCA2 – Breast, ovarian, prostate, pancreatic cancers
• EGFR – Non-small cell lung cancer (NSCLC), glioblastoma
• KRAS / NRAS – Colorectal, lung, pancreatic cancers
• BRAF – Melanoma, colorectal, thyroid cancers
• ALK, ROS1, HER2, PIK3CA, TP53 – Across multiple solid tumors

This test is essential for:

• Guiding FDA-approved targeted therapies (e.g., osimertinib for EGFR+, olaparib for BRCA+)
• Avoiding ineffective treatments (e.g., anti-EGFR drugs in KRAS-mutant CRC)
• Identifying hereditary cancer syndromes (e.g., BRCA, Li-Fraumeni)
• Monitoring treatment response or resistance in advanced disease

With results in just 10–14 days, Lab Tests Dubai empowers oncologists to deliver precise, evidence-based care—so patients receive the right drug for their tumor’s DNA.

Available through partner oncology centers, this flexible panel ensures accurate, actionable, and patient-centered cancer genomics.

Why You Need This Test

If you or a loved one has been diagnosed with cancer, this test could reveal the specific genetic drivers of the tumor—so your doctor can skip ineffective chemo and go straight to precision medicine.

You need the Custom 4-Gene NGS Panel if:

• You have lung, breast, colorectal, ovarian, or pancreatic cancer
• Your oncologist wants to test for specific mutations (e.g., EGFR, BRCA)
• You’re considering targeted therapy or PARP inhibitors
• You have a family history of hereditary cancers
• You want cost-effective genomic testing without unnecessary genes
• You’re exploring clinical trial eligibility based on biomarkers

This test helps:

• Match you to targeted drugs approved for your mutation
• Avoid side effects from ineffective chemotherapy
• Identify inherited risk for family members
• Monitor tumor evolution over time
• Make faster, smarter treatment decisions

Precision  better outcomes, fewer side effects.

Who Should Consider This Test?

The Custom 4-Gene NGS Panel is recommended for:

✅ Patients with Solid Tumors
Lung, breast, colorectal, ovarian, prostate, melanoma, pancreatic cancers.

✅ Those Seeking Targeted Therapy
Especially when standard treatments are limited.

✅ Individuals with Family History of Cancer
To assess hereditary risk (e.g., BRCA, TP53).

✅ Oncologists & Medical Teams
Wanting rapid, focused molecular profiling.

✅ Patients on Treatment or with Recurrence
To detect new mutations driving resistance.

This test is ideal when broad panels aren’t needed but precision matters most.

What Does the Test Reveal?

Using next-generation sequencing (NGS), the panel detects:

• 🔬 Single Nucleotide Variants (SNVs) – e.g., EGFR L858R
• 🔬 Insertions/Deletions (Indels) – e.g., EGFR exon 19 deletion
• 🔬 Copy Number Variations (CNVs) – gene amplifications (e.g., HER2)
• 🔬 Gene Fusions – if relevant (e.g., ALK-EML4)

Key Clinical Implications:

Results are interpreted using NCCN, ESMO, and FDA guidelines so your oncologist gets actionable, up-to-date recommendations.

What Happens If You Skip Genomic Testing?

Without targeted gene testing, patients may:

⚠️ Receive ineffective chemotherapy or biologics
⚠️ Miss life-extending targeted therapies
⚠️ Overlook hereditary risks affecting family members
⚠️ Experience delayed diagnosis or progression
⚠️ Be excluded from clinical trials due to lack of biomarker data

The good news? Many cancers now have targeted treatments:

• Osimertinib for EGFR+ lung cancer → longer survival
• Olaparib for BRCA+ ovarian cancer → delays recurrence
• Dabrafenib + Trametinib for BRAF+ melanoma → high response rate

Early testing  longer, higher-quality survival.

How to Prepare for the Test

To ensure accurate results:

✅ Sample Type:

• Tissue: FFPE block or biopsy (primary or metastatic)
• Blood: For germline testing or liquid biopsy (cfDNA) in advanced cases

✅ No fasting or special prep required
✅ Provide clinical history (cancer type, stage, prior treatments)
✅ Your doctor will coordinate sample submission from pathology lab

The lab performs DNA extraction, library prep, NGS sequencing, and bioinformatics analysis all under strict quality control.

Test Overview: Custom 4-Gene NGS Panel

Report Includes:

• List of tested genes and detected variants
• Variant classification (Pathogenic, VUS, Benign)
• Therapeutic implications (approved drugs, trials)
• Hereditary risk flags (for genetic counseling)

Note: Ideal for focused testing when full panels are not indicated.

Benefits of the Custom 4-Gene NGS Panel

🔹 Tailored to Your Needs
Test only the genes that matter for your cancer.

🔹 Cost-Effective Precision
Lower cost than large panels, same accuracy.

🔹 Guides Targeted Therapy
Match patients to effective, less toxic drugs.

🔹 Supports Hereditary Screening
Identify BRCA or TP53 mutations in families.

🔹 Fast & Actionable
Helps doctors decide quickly—critical in advanced disease.

If you’re facing cancer and want personalized treatment, the NGS Cancer Gene Panel (4-Gene) gives you the answers you need in 10–14 days.